Cartilago, a clinical stage regenerative medicine company, has announced a clinical study for Regen Longevity, a regenerative peptide candidate being developed to increase overall skin health and for the treatment of facial wrinkles that occur with ageing. The clinical study is designed to test the efficacy and safety of the cosmetic product.
The anti-ageing treatment was developed to enhance the overall health of ageing skin and to improve the appearance of expression lines. The cream formulation comprises a proprietary peptide, a derivative of glucosamine that displayed potent regenerative capacity in first-in-human studies, with visible reduction of fine and course facial wrinkles, with improved skin evenness and hydration. The clinical study will be conducted in partnership with The Statale University of Milan as a randomized, double-blind, placebo-controlled clinical trial with 50 subjects over the course of 12 weeks. The study is planned to initiate in the fourth quarter of 2021.
“Initiating the clinical study for Regen Longevity will be a pivotal milestone in our endeavor to develop a best-in-class, clinically-validated anti-ageing skin treatment” commented Dr. Filippo Surace, Co-founder and Executive Chairman of Cartilago. “We believe Regen Longevity’s regenerative peptide holds the promise to be a breakthrough solution for reversing skin ageing.”
Cartilago is a clinical stage regenerative medicine company that develops disease-modifying, chondroprotective technologies for combatting osteoarthritis and related pathologies, and anti-ageing solutions for skincare and wound care. Cartilago’s regenerative technologies are centered upon peptides that display extraordinary potency in stimulating the production of new cartilage tissue, as well as the generation of extracellular matrix and collagen, and the endogenous production of hyaluronic acid.